A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
Latest Information Update: 19 Nov 2019
At a glance
- Drugs Cobiprostone (Primary)
- Indications Portal hypertension
- Focus Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 16 Mar 2016 Status changed from completed to discontinued, according to ClinicalTrials.gov record.
- 30 May 2014 New trial record